PYPD PolyPid Ltd.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1611842 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY—
TTM net income YoY-17.7%
TTM EPS YoY-57.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-366.3%
ROA-143.8%
ROIC (approx.)-1,290.9%
Asset turnover—
Leverage & solvency
Liabilities / assets50.8%
Debt / equity0.00x
Current ratio1.97x
Interest coverage-37.72x
Cash quality & payout
Operating cash flow / net income0.82x
Accruals ratio-26.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $23.81M | $22.81M |
| SG&A expense | $7.18M | $4.27M |
| Operating income | -$32.97M | -$28.03M |
| Interest expense | $874,000 | $1.51M |
| Pretax income | -$34.16M | -$28.98M |
| Income tax | $5,000 | $42,000 |
| Net income | -$34.17M | -$29.02M |
| EBITDA | -$31.51M | -$26.41M |
| EPS (basic) | 2.09 | 4.91 |
| EPS (diluted) | 2.09 | 4.91 |
| Weighted avg. shares (diluted) | 16.35M | 5.91M |
| Balance sheet | ||
| Cash & equivalents | $6.40M | $15.64M |
| Current assets | $15.23M | $16.57M |
| PP&E, net | $5.09M | $6.08M |
| Total assets | $22.31M | $25.22M |
| Current liabilities | $7.74M | $12.68M |
| Short-term debt | $988,000 | $6.79M |
| Long-term debt | — | $634,000 |
| Total debt | — | $7.42M |
| Total liabilities | $11.33M | $17.54M |
| Shareholders' equity | $10.97M | $7.68M |
| Net debt | — | -$8.22M |
| Shares outstanding | 18.20M | 10.19M |
| Cash flow statement | ||
| Operating cash flow | -$27.88M | -$21.96M |
| Capital expenditure | $210,000 | $76,000 |
| Free cash flow | -$28.09M | -$22.04M |
| Investing cash flow | -$6.70M | -$330,000 |
| Financing cash flow | $25.37M | $32.42M |
| Depreciation & amortization | $1.46M | $1.62M |
| Stock-based compensation | $4.85M | $2.82M |
Free plan shows the latest 2 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.